Top Story
The Blockbuster Model: Alive and Well
Over the past decade, many industry journalists, analysts, and consultants presumed that specialty markets, pricing pressures, and pharmacogenetic testing would kill off billion-dollar products. However—to paraphrase Mark Twain—reports of the death of the blockbuster have been widely exaggerated, write Stan Bernard and Janet Wells.
...Read more
Pharma 50
Pharm Exec’s Top 50 Pharma Companies
Our annual Pharma 50 listing is clear proof that once-small and midsize biopharma companies are moving up to join the top ranks of big Pharma. Specialty drug sales, record-breaking M&A paired with tax synergies, and global expansion helped to bring a new face into this year’s Pharma 50 top 10, and substantially boosted the rankings of several others.
...Read more
Scientifically Minded, Medically Driven
You work tirelessly to bring better products to market and improve patients’ lives. At WCT, we support you by consistently delivering quality results, on-time, on-budget and always bolstered by unrivaled science and medicine. Flexible. Reliable. Committed
.
 We aren’t satisfied until you are.
Pharma 50
Pharma 50 Slide Show
If you’re pressed for time, and require “just the facts”, click here for a quick rundown of the Pharma Top 50 list.
...Read more
On the road to integration
Moving your multichannel program into the fast lane
Live webcast: Wednesday, 1 July 2015 at 11 am EDT | 16:00 BST | 17:00 CEST
Join Peter Lammers and Liz Murray from Quintiles as they present insightful research findings regarding the state of the pharmaceutical industry and the use of multi-channel marketing strategies. Learn what other industries apply successfully and get different options for you to actually “make it happen” for your product.
 Register for free
Europe
What Price a Greek Exit from the European Union?
Today Greece has its second crisis meeting with the EU in less than a week. With the talk shifting (again) to the country's exit from the eurozone, what might the implications be for pharma?
...Read more
Breaking through the complexity
Improving oncology treatment and access in the UK
Live webcast: 30 June 2015 at 9 am EDT | 14:00 BST | 15:00 CEST
Join Dean Summerfield, Senior Vice President, Commercial and Consulting from Quintiles and Dr Jason Lester, Consultant Clinical Oncologist at the Velindre Cancer Centre as they discuss improving innovative oncology treatment and access in the UK.
 Register for free
Legal
Sales Personnel Contracts, Sword or Shield for M&A Valuation
Determining a company’s acquisition/merger value requires an intensive due diligence process. Attorney Gregg Metzger discusses sales force contracts which, especially for life science companies, cannot be overlooked.
...Read more
Patient adherence in Germany - benefit vs. cost-containment
Live webcast: Wednesday, 24 June 2015 at 11 am EDT | 16:00 BST | 17:00 CEST
Join Joanne Thiele, Market Access Project Manager from Quintiles Germany and Hans Holger Bleß, Director of Health Services Research department at IGES Institut GmbH as they discuss the importance of patient adherence programs in Germany.
 Register for free
|
|
|
 //Cellerant Therapeutics (San Carlos, CA) announced that Rodney Young joined the Company as Chief Financial Officer. //Greg Stea joined Achaogen’s (South San Francisco, CA) Board of Directors as a Class II Director.
//Robert E. Hoffman is to leave Arena Pharmaceuticals (San Diego, CA), where he serves as Senior Vice President, Finance and Chief Financial Officer. He will remain in the role until July 10. //NeoGenomics (Fort Myers, FL) elected Alison L. Hannah, M.D. and Lynn A. Tetrault its Board of Directors at its Annual Meeting of Shareholders on June 12. //Tocagen (San Diego, CA) appointed Asha Das, M.D., as Vice President of Clinical Development and Medical affairs. // |
|
